HC Wainwright Forecasts Lower Earnings for Nuvation Bio

Nuvation Bio Inc. (NYSE:NUVB) – Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Nuvation Bio in a research note issued on Thursday, January 23rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.16) for the quarter, down from their previous forecast of ($0.14). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.73 million for the quarter.

Several other equities research analysts have also recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective (up previously from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.20.

Nuvation Bio Stock Down 1.8 %

NYSE NUVB opened at $2.46 on Monday. Nuvation Bio has a fifty-two week low of $1.52 and a fifty-two week high of $4.16. The business has a fifty day moving average of $2.73 and a 200-day moving average of $2.78. The stock has a market cap of $826.28 million, a price-to-earnings ratio of -1.13 and a beta of 1.47.

Institutional Trading of Nuvation Bio

Hedge funds have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. acquired a new position in shares of Nuvation Bio in the 3rd quarter worth approximately $2,790,000. Dimensional Fund Advisors LP lifted its stake in Nuvation Bio by 415.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock worth $2,975,000 after purchasing an additional 820,669 shares during the last quarter. Wexford Capital LP boosted its holdings in Nuvation Bio by 930.2% in the third quarter. Wexford Capital LP now owns 651,767 shares of the company’s stock worth $1,493,000 after purchasing an additional 588,500 shares during the period. FMR LLC increased its stake in Nuvation Bio by 1.4% during the third quarter. FMR LLC now owns 29,238,871 shares of the company’s stock valued at $66,957,000 after purchasing an additional 416,932 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Nuvation Bio by 479.1% during the third quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company’s stock worth $1,014,000 after purchasing an additional 366,429 shares during the period. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.